



RECEIVED  
JAN 28 2003  
TECH CENTER 1600/2800

PATENTS  
Attorney Docket No. VOS-27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Karin Molling et al.  
Application No. : 10/047,539 Confirmation No. : 4984  
Filed : January 15, 2002  
For : PHARMACEUTICAL COMPOSITIONS FOR TREATING  
OR PREVENTING CANCER  
Group Art Unit : 1633  
Examiner : Not yet assigned

New York, New York 10020  
January 21, 2003

Hon. Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,  
through their representatives, make of record the following  
documents:\*

United States Patent

<u>Patentee</u>	<u>Patent No.</u>	<u>Issue Date</u>
Kawakami et al.	5,844,075	December 1, 1998

\* A completed Form PTO-1449 listing these documents is attached hereto.

Other Documents

Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmel17," *Leukemia*, 13:S48-S51 (1999).

Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," *Immunology Today*, 18:175-182 (1997).

Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," *Cancer Research*, 58:2509-2514 (1998).

Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned certifies that each of the documents listed in this Information Disclosure Statement was cited in a December 12, 2002 European Search Report of European Application No. EP 02 00 0185 ("the European Search Report"), the European counterpart of the above-identified application.

The European Search Report was mailed not more than three months prior to the filing of this statement. A copy of the European Search Report is submitted herewith.

Applicant respectfully requests that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicant also requests that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Respectfully submitted,

*H. Hale*

---

James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Karen E. Brown (Reg. No. 43,866)  
Greg A. Morris (Reg. No. P-53,349)  
Agents for Applicants  
FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090

I hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. BOX 2027  
ARLINGTON, VA 22214-2027

January 21, 2003  
Lillian Garcia  
Lillian Garcia  
Signature of Person Signing

O I P T O R M P T O - 1 4 4 9 JAN 27 2003 U.S. PATENT AND TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VOS-27	APPLICATION NO. 10/047,539
	INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	APPLICANTS Karin Mölling et al.	CONFIRMATION NO. 4984
	FILING DATE January 15, 2002	GROUP 1633	

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmel17," <i>Leukemia</i> , 13:S48-S51 (1999).
	Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," <i>Immunology Today</i> , 18:175-182 (1997).
	Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," <i>Cancer Research</i> , 58:2509-2514 (1998).

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



# RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

PATENTS

Attorney Docket No. VOS-27

#6  
1633 *dia*  
3/3/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Karin Molling et al.

Application No. : 10/047,539 Confirmation No. : 4984

Filed : January 15, 2002

For : PHARMACEUTICAL COMPOSITIONS FOR TREATING  
OR PREVENTING CANCER

Group Art Unit : 1633

Examiner : Not yet assigned

New York, New York 10020  
January 21, 2003

Hon. Commissioner for Patents  
Washington, D.C. 20231

## TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97(b) (3), submission of this Statement requires no fee. However, in the event that the first Office Action on the merits has been issued, this Statement is accompanied

by a certification as required under 37 C.F.R. §§ 1.97(c)(1) and 1.97(e)(1). Thus, no fee is required.

If for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,




---

James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Karen E. Brown (Reg. No. 43,866)  
Greg A. Morris (Reg. No. P-53,349)  
Agents for Applicants  
FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090

I hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. BOX 2227  
ARLINGTON, VA 22202-2227

January 21, 2003  
Lillian Garcia

  
Signature of Person Signing

 <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANTS</b>	ATTY. DOCKET NO. VOS-27	APPLICATION NO. 10/047,539
	APPLICANTS Karin Mölling et al.	CONFIRMATION NO. 4984
	FILING DATE January 15, 2002	GROUP 1633

## U.S. PATENT DOCUMENTS

---

**FOREIGN PATENT DOCUMENTS**

---

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

SEARCHED DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
EXAMINER INITIAL	
	Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmel17," <i>Leukemia</i> , 13:S48-S51 (1999).
	Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," <i>Immunology Today</i> , 18:175-182 (1997).
	Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," <i>Cancer Research</i> , 58:2509-2514 (1998).

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.